Monthly Archives

March 2019

Anne Lindblad, Ph.D., President, and CEO of Emmes, joins Rich Bendis for BioTalk

By | News | No Comments

BioTalk Host Rich Bendis sits down with Anne Lindblad, Ph.D., President, and CEO of Emmes, to discuss her view of the region, her history with the company, and their mission, vision, and values.

Anne Lindblad, Ph.D., joined Emmes in 1982 as a Biostatistician and is currently the President and CEO. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry. Dr. Lindblad has been an NIH reviewer on multiple project applications for NINDS, NEI, NICHD, NIDCR, NIDDK, and NCCAM and has served as a member or chair of several Data and Safety Monitoring Committees for NEI, NIAAA, NIDDK, and NINDS. She was a member of an Advisory Committee charged with drafting policy to shape the appropriate planning and conduct of intramural studies at NIH. She was elected to the Board of Directors for the Society for Clinical Trials (2003-2006) and served as Program Chair (2002), as an Officer (2006-2014), and as President (2012-2013). Dr. Lindblad was selected to serve on NIH’s National Advisory Dental and Craniofacial Research Council from 2004 through 2008. She has taught courses in best practices in clinical trial design and conduct for ophthalmologists, neurologists, and immunologists. She has published and presented over 100 manuscripts in peer-reviewed journals and conferences. Dr. Lindblad joined the Board of BioHealth Innovation in 2018.  Emmes has grown from 15 employees in 1982 to over 650 globally. In 2019 Emmes announced a significant investment by Behrman Capital which will allow Emmes to gain access to new tools, talent, service offerings, and expanded footprint faster than what Emmes might otherwise have accomplished.

Listen now on iTunesGoogle Play, and TuneIn.

Successful Marketing & PR Strategies for Your Startup (4/4)

By | News | No Comments
  • bhi-updated-logo-2017PR and Marketing – What’s the difference?
  • How do you establish your brand?
  • Are their tips for marketing on a tight budget?
  • What should an effective marketing plan include?
  • How can a strong digital strategy build credibility?
  • How can I get press coverage for my product/service/technology?
  • What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee
8:30 a.m.  – Issues Overview and Discussion (in person/by videoconference)

  • Pam Clark, Principal, Creative Director – Clark Concepts
  • Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
  • Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
  • Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

To register/for more information, email:  BHI@BioHealthInnovation.   (Please include in your RSVP:  Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

Osiris to be acquired by British medical device company for $660.5M

By | Uncategorized | No Comments

A British medical device manufacturing company plans to acquire Osiris Therapeutics Inc. for $660.5 million.

Smith & Nephew plc will pay $19 per share for Osiris in the all-cash deal expected to close in the second quarter. Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud. Osiris develops products for wound care, orthopedics and sports medicine using stem cells.

London-based Smith & Nephew is paying a 37 percent premium from the 90-day weighted average stock price. Shares of Osiris were up less than 1 percent in trading Tuesday morning to $19.03.

Peter Friedl, chairman and co-founder of Osiris, said in a statement the deal is a “very good outcome” for shareholders and will help “take the business to the next level.”

“I am immensely proud of the business we have built from our research into advanced regenerative technologies,” Friedl said. “I believe Smith & Nephew is the right home for Osiris and will allow our products to reach more customers, helping to restore quality of life for more patients.”

All 360 of Osiris’ employees are expected to join Smith & Nephew upon completion of the deal.

Click here to read more via the Baltimore Business Journal.

TEDCO Generates $1.6 Billion in Economic Benefits to the State of Maryland and Supports 7,746 Maryland Jobs, According to New Independent Study

By | News | No Comments

COLUMBIA, Md. (March 6, 2019)— The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.

Conducted by Richard Clinch of the University of Baltimore’s Jacob France Institute and Mitch Horowitz of TEConomy Partners (JFI-TEConomy), the study found that TEDCO is a significant economic driving force, supporting 7,746 Maryland jobs and more than $1.6 billion in statewide economic activity in 2018.

The study says TEDCO has generated significant economic and fiscal returns to the state. Reviewing the change from 2015 to 2018, TEDCO’s economic impact included job creations from 4,358 in 2015 to 7,746 in 2018. TEDCO’s total economic impact has also seen a significant increase from $1B in 2015 to $1.6B in 2018. The jobs supported by these companies earn $600.1 million in labor income and generate estimated state and local government revenues of $66.6 million, according to the study.

By 2023, the study projects TEDCO’s economic impact will increase substantially to $2.4B and will support a total of 11,812 jobs.

Click here to read more via TEDCO

These 3 tech investors are the most active in the DMV: report

By | Uncategorized | No Comments

Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.

The report looks at the most active venture capital firms in each U.S. state based on unique tech portfolio investments. Chevy Chase, Md.-based New Enterprise Associates (NEA) was listed as the most active tech investor in the District while CIT GAP Funds topped the list in Virginia and TCP Venture Capital in Maryland. The report looked at their unique tech investments between 2014 and Jan. 24, 2019.

CB Insights said it excluded debt deals and only considered venture capital, corporate venture capital, super angel and growth equity firms. In the case of a tie, CB Insights used recency of deals, overall deal activity and investor quality. NEA was the only firm to lead more than one state with the most investments in D.C. and New Jersey. CB Insights’ last conducted this report in May 2017 and since then, there has been 21 changes in the top investor slots. According to CB Insights, Fortify Ventures led the way in D.C back in May 2017.

Click here to read more via Technic.ly DC

Behrman Capital Makes Significant Investment in Emmes

By | News | No Comments

ROCKVILLE, Md.March 4, 2019 /PRNewswire/ — Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company.  The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Behrman Capital has a 25-year track record of successfully investing in growing healthcare services companies, adding resources and professional services to help them innovate and expand.

“This is a substantial and exciting milestone in our evolution,” said Dr. Anne Lindblad, president and chief executive officer of Emmes.  “The Emmes name will continue, as will our vision, mission, leadership, and focus on advancing human health.  We will benefit from Behrman’s investment, expertise and relationships.  We believe this investment will allow us to provide employees even greater opportunities as we continue to build and grow.

“Our government work is and will remain core, and we plan to accelerate our efforts on the non-government side,” she added.

According to Grant Behrman, managing partner of Behrman Capital, “Emmes has world class talent and an outstanding reputation in clinical research.  It has built an especially strong legacy in the government sector and, in particular, at the National Institutes of Health.  Our role is to invest in the company’s future growth, from employee development to expanded offerings to current and prospective clients.”

Click here to read the entire release vis PR Newswire

Join our Mailing List